The estimated Net Worth of James F Barlow is at least $410 Tysiąc dollars as of 14 June 2024. Mr. Barlow owns over 3,131 units of Arcturus Therapeutics Inc stock worth over $275,488 and over the last 5 years he sold ARCT stock worth over $0. In addition, he makes $135,006 as Independent Director at Arcturus Therapeutics Inc.
Sign up
Mr. Barlow ARCT stock SEC Form 4 insiders trading
James has made over 1 trades of the Arcturus Therapeutics Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 3,131 units of ARCT stock worth $65,688 on 14 June 2024.
The largest trade he's ever made was exercising 3,131 units of Arcturus Therapeutics Inc stock on 14 June 2024 worth over $65,688. On average, James trades about 522 units every 0 days since 2019. As of 14 June 2024 he still owns at least 13,131 units of Arcturus Therapeutics Inc stock.
You can see the complete history of Mr. Barlow stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Barlow biography
James F. Barlow serves as Independent Director of the Company. Mr. Barlow is a C-level financial executive with more than 30 years of experience leading teams in the successful strategic achievement of financial and operational goals, and expertise in domestic and international operations, financial planning, forecasting and reporting, restructurings, business development and integrations, treasury and investor relations. As an Executive Officer (Principal Accounting Officer) at Allergan, Inc. from January 2002 to March 2015, he oversaw financial due diligence, integration and structuring for all significant asset purchases, sales, business combinations and licensing transactions, the spin-off of Advanced Medical Optics, the $3.3 billion acquisition of Inamed Corporation and more than $4.5 billion in other transactions. He ensured consistent application of corporate policies and procedures and alignment with global reporting and corporate compliance requirements, made recommendations globally to improve financial operations and participated in robust financial planning forecasting activities. Prior to joining Allergan, Mr. Barlow served as Chief Financial Officer of Wynn Oil Company, a division of Parker Hannifin Corporation, during 2001, Treasurer and Controller of Wynn’s International, Inc. from 1990 to 2000 and Vice President and Controller of Ford Equipment Leasing Company from 1986 to 1990. From 1983 to 1985 Mr. Barlow worked for the accounting firm Deloitte Haskins and Sells. Mr. Barlow received a Bachelor of Science degree in Accounting, graduating magna cum laude, from Brigham Young University and a Master of Accountancy, graduating with honors—high distinction, from Brigham Young University. He is a certified public accountant (inactive). Mr. Barlow is nominated for re-election on our Board of Directors because of his significant experience as an executive and director of a number of companies in the healthcare sector, and because of his financial and accounting expertise.
What is the salary of James Barlow?
As the Independent Director of Arcturus Therapeutics Inc, the total compensation of James Barlow at Arcturus Therapeutics Inc is $135,006. There are 11 executives at Arcturus Therapeutics Inc getting paid more, with Andrew Sassine having the highest compensation of $1,326,880.
How old is James Barlow?
James Barlow is 61, he's been the Independent Director of Arcturus Therapeutics Inc since 2018. There are 2 older and 9 younger executives at Arcturus Therapeutics Inc. The oldest executive at Arcturus Therapeutics Holdings Inc is Edward Holmes, 79, who is the Independent Director.
What's James Barlow's mailing address?
James's mailing address filed with the SEC is C/O ARCTURUS THERAPEUTICS HOLDINGS INC., 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO, CA, 92121.
Insiders trading at Arcturus Therapeutics Inc
Over the last 12 years, insiders at Arcturus Therapeutics Inc have traded over $137,035,874 worth of Arcturus Therapeutics Inc stock and bought 56,234 units worth $767,374 . The most active insiders traders include William M Kahane, Nicholas S Schorsch oraz Peter C Farrell. On average, Arcturus Therapeutics Inc executives and independent directors trade stock every 33 days with the average trade being worth of $1,034,818. The most recent stock trade was executed by Jing L. Marantz on 14 June 2024, trading 3,131 units of ARCT stock currently worth $65,688.
What does Arcturus Therapeutics Inc do?
founded in 2013 and based in san diego, calif., arcturus therapeutics is poised to become an industry leader in the application of rnai technologies for the treatment of disease and improved quality of life. the company’s aim is to develop breakthrough technology and novel therapeutics for rare diseases for which there is no adequate treatment. backed by a management team with extensive experience in the discovery and development of therapeutic modalities, arcturus is on the forefront of research and development of nanoparticle sirna drug delivery systems.
What does Arcturus Therapeutics Inc's logo look like?
Complete history of Mr. Barlow stock trades at Arcturus Therapeutics Inc
Arcturus Therapeutics Inc executives and stock owners
Arcturus Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Andrew Sassine,
Chief Financial Officer, Director -
Joseph Payne,
President, Chief Executive Officer, Director -
Joseph E. Payne M.Sc.,
Founder, Pres, CEO & Director -
Dr. Steven George Hughes M.B.A., M.D.,
Chief Medical Officer -
Dr. Padmanabh Chivukula,
Founder, Chief Scientific Officer, COO & Sec. -
Andrew H. Sassine,
CFO & Director -
Padmanabh Chivukula,
Chief Operating Officer, Chief Scientific Officer -
Lance Kurata,
Chief Legal Officer -
Karah Parschauer,
Director -
Edward Holmes,
Independent Director -
Peter Farrell,
Independent Chairman of the Board -
Magda Marquet,
Independent Director -
James Barlow,
Independent Director -
Steven Hughes,
Chief Development Officer -
Dr. Nirdosh Jagota Ph.D.,
Exec. VP & Chief Regulatory Officer -
Kevin T. Skol,
Sr. VP of Bus. Devel. & Alliance Management -
Neda Safarzadeh,
Sr. Director and Head of Investor Relations/PR & Marketing -
Dr. Dushyant B. Varshney Ph.D.,
Exec. VP & Chief Technology Officer -
Keith C. Kummerfeld CPA,
VP of Fin. & Corp. Controller -
Capital Group, Lpluxor Capi...,
-
William G Stanley,
Director -
Leslie D Michelson,
Director -
Susan E Manning,
See Remarks -
William M Kahane,
President and CEO -
Brian D Jones,
CFO and Treasurer -
Nicholas S Schorsch,
Director -
Robert Burns,
Director -
Pad Chivukula,
Chief Scientific Officer & COO -
Keith C Kummerfeld,
See Remarks -
Andy Sassine,
Chief Financial Officer -
Lance Kurata,
Chief Legal Officer -
Pharmaceutical Inc. Ultragenyx,
Director -
Jing L. Marantz,
Director -
John Markels,
Director -
Moncef Slaoui,
Director